Enliven Therapeutics (ELVN) stock has drawn investor attention after recent trading, which left the company valued at about US$2.9b and its shares closing at US$49.12, alongside mixed annual revenue and net income growth figures.

At the current share price of US$49.12, Enliven Therapeutics has seen strong momentum, with a 1 month share price return of 15.49% and a year to date share price return of 216.09%, alongside a 1 year total shareholder return of 128.25% that points to substantial longer term gains.

If Enliven Therapeutics has caught your eye, this could be a good moment to see what else is moving in healthcare, especially via the 39 healthcare AI stocks

With Enliven Therapeutics still loss making and carrying a value score of 2, yet trading close to analyst expectations with around a 22% gap to the price target, investors have to ask: is this a genuine opportunity, or is the market already pricing in future growth?

Preferred Price-to-Book Multiple of 6.6x: Is it justified?

On a P/B of 6.6x, Enliven Therapeutics trades at a level that sits below a selected peer average of 8.4x, yet remains well above the broader US pharmaceuticals industry average of 2.2x.

The P/B ratio compares a company's market value to its book value. This can be a useful reference for a clinical stage biopharmaceutical stock like Enliven Therapeutics that is still loss making and has minimal current revenue. At 6.6x book, investors are effectively paying a sizeable premium over net assets, which often reflects expectations around the future potential of the pipeline rather than current earnings power.

Relative to the peer group P/B of 8.4x, Enliven Therapeutics screens as better value. This suggests the stock is not the highest priced option in that set on this metric. However, compared to the wider US pharmaceuticals industry average of 2.2x, its 6.6x multiple is roughly three times higher. This indicates the market is assigning a materially higher valuation than the typical company in the sector and implies that expectations for future progress are already embedded in the price.

Result: Price-to-book of 6.6x (ABOUT RIGHT)

However, Enliven Therapeutics still reports annual net losses of US$98.777m and depends on successful clinical trial outcomes, so pipeline setbacks could quickly challenge the current valuation narrative.

Next Steps

With Enliven Therapeutics attracting both enthusiasm and caution, it makes sense to review the underlying data yourself and then decide how the risk reward trade off stacks up through the 2 key rewards and 4 important warning signs

Looking for more investment ideas beyond Enliven Therapeutics?

If Enliven Therapeutics has sharpened your focus on opportunities, do not stop here. Broaden your watchlist with ideas that match your goals and risk comfort.

• Target potential upside in lower priced stocks with healthier fundamentals by reviewing the 22 elite penny stocks with strong financials.
• Hunt for companies that pair solid business quality with appealing valuations by scanning the 43 high quality undervalued stocks.
• Prioritise resilience and aim to sleep better at night by checking the 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.